Table 1.
Vaccination trials for C. jejuni infection in poultry (modified from [49]).
| Vaccine Type | Vaccine Active Components | Route of Administration | C. jejuni Challenge Strain/Dose per Bird | Effect on Campylobacter Colonization | Reference |
|---|---|---|---|---|---|
| Whole-cell vaccines | Whole cell (WC) and flagellin (Fla) or purified Fla |
Intra-peritoneally (IP) followed by an IP or oral booster doses |
C. jejuni, isolate #V2 (by mixing with seeder chickens) |
WC+Fla (twice IP): Up to 2 log10 CFU/g WC+Fla (IP and orally) or Fla alone: No reduction |
[45] |
| Formalin inactivated WC with or without LT adjuvant | Esophageal gavage |
C. jejuni, F1BCB (by mixing with seeder chickens) |
WC alone: Up to 0.4 log10 on day 7 WC+LT: Up to 1.9 log10 on day 46 |
[46] | |
| Wild-type parental strain or the mutated strains (CadF9, CiaB5, PldA23, and DnaJA) | Intraperitoneal | C. jejuni F38011 (104 CFU) | Up to 0.9 log10 CFU/g in CiaB5 group only | [50] | |
| C. jejuni NCTC 11168 isogenic knockout mutants of AhpC, KatA, and SodB | Oral |
C. jejuni NCTC 11168 (1 × 108 CFU) |
ΔahpC mutant: Up to 3 log10 ΔkatA: Up to 2 log10 ΔsodB: No effect on day 42 of age |
[51] | |
| Subunit vaccines | C. jejuni N-glycan with GlycoTag, or fused to the E. coli lipopolysaccharide-core | Oral |
C. jejuni, 81–176 (102 or 106 CFU) |
10 log10
reduction on day 35 |
[52] |
|
FlaA/CadF/FlpA/CmeC protein or CadF-FlaA-FlpA fusion protein |
Intramuscular |
C. jejuni F38011 (2 × 108 CFU) |
≥3 log10 on day 35 | [53] | |
| Capsular polysaccharide conjugated to diphtheria toxoid CRM | Subcutaneous |
C. jejuni 81–176 (2 × 107 CFU) |
0.64 log10 CFU/g on day 38 of age |
[54] | |
|
C. jejuni outer membrane proteins |
Subcutaneous/Oral |
C. jejuni, 81–176 (1 × 108 CFU) |
SC: Below the detection limit (<10 CFU) Oral: No protection on day 42 of age |
[55] | |
| C. jejuni Enterobactin-KLH conjugate | Intramuscular |
C. jejuni, NCTC 11168 (1 × 104 CFU) |
>4 log10 on day 58 of age |
[56] | |
| Recombinant vaccines |
E. coli expressing N-glycan protein with probiotics (A. mobilis DSM 15930 or L. reuteri CSF8) |
Oral |
C. jejuni, 81–176 (106 CFU) |
Up to 6 log10 on day 35 | [57] |
| S. Typhimurium ΔaroA mutant expressing CjaA as a plasmid-encoded fusion to fragment C of tetanus toxin | Subcutaneous /Oral |
C. jejuni, MI (1 × 107 CFU) |
Oral: 1.4 log10 CFU/g Subcutaneous: 3.78 log10 |
[58] | |
| Salmonella strain carrying C. jejuni 72Dz/92 CjaA gene | Oral |
C. jejuni, pUOA18 (2 × 108 CFU) |
6 log10 at 12 days post challenge | [59] | |
| Nanoparticle-based vaccines | Chitosan/pCAGGS-flaA nanoparticles | Intranasal |
C. jejuni ALM-80 (5 × 107 CFU) |
2 log10 CFU/g on day 35 of age | [60] |
| PLGA-encapsulated C. jejuni outer membrane proteins | Subcutaneous /Oral |
C. jejuni 81–176 (1 × 108 CFU) |
SC: Below the limit of detection Oral: No protection on day 42 of age |
[55] | |
| Liposome encapsulated proteins (CjaALysM and CjaDLysM) | In ovo |
C. jejuni 12/2 (106 CFU) |
2 log10 CFU/g on day 28 of age | [61] | |
| PLGA-encapsulated CpG ODN and C. jejuni lysate | Oral |
C. jejuni, (81–176/ 107 CFU) |
Up to 2.4 log10 on day 37 of age | [62] |